Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irreversible electroporation plus nivolumab in metastatic pancreatic cancer
2020-004623-17Phase 2Terminated
- Sponsor
- Zealand University Hospital
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in pancreatic cancer (PC), pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PDAC), sponsored by Zealand University Hospital. Primary endpoint: Safety of nivolumab in combination with irreversible electroporation. Started Oct 2020; status: terminated.
02
Drugs
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)pancreatic cancer (PDAC)
Beyond the preview
Go deeper on 2020-004623-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004623-17.